Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD20-targeted CAR-T immunotherapy

DRUG CLASS:

CD20-targeted CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	JNJ-4496 Sensitive: B - Late Trials JNJ-4496 Sensitive : B	JNJ-4496 Sensitive: B - Late Trials JNJ-4496 Sensitive : B
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials IMPT-314 Sensitive : B	IMPT-314 Sensitive: B - Late Trials IMPT-314 Sensitive : B
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials IMPT-314 Sensitive : B	IMPT-314 Sensitive: B - Late Trials IMPT-314 Sensitive : B
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	MB-106 Sensitive: C3 – Early Trials MB-106 Sensitive : C3	MB-106 Sensitive: C3 – Early Trials MB-106 Sensitive : C3
CD20 expression	Lymphoma	CD20 expression	Lymphoma	ADI-001 Sensitive: C3 – Early Trials ADI-001 Sensitive : C3	ADI-001 Sensitive: C3 – Early Trials ADI-001 Sensitive : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	CD20-targeted CAR-T immunotherapy + venetoclax Sensitive: D – Preclinical CD20-targeted CAR-T immunotherapy + venetoclax Sensitive : D	CD20-targeted CAR-T immunotherapy + venetoclax Sensitive: D – Preclinical CD20-targeted CAR-T immunotherapy + venetoclax Sensitive : D